Vor Biopharma Inc
VOR0.151USD
-0.008-5.44%
Fechamento 05/09, 16:00（ET）Cotações atrasadas em 15 min
18.88MValor de mercado
PerdaP/L TTM
Mais detalhes de Vor Biopharma Inc Empresa
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.
Informações da empresa
Código da empresaVOR
Nome da EmpresaVor Biopharma Inc
Data de listagemFeb 05, 2021
Fundado em2015
CEODr. Robert Ang, M.D.
Número de funcionários159
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
Endereço100 Cambridgepark Drive
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Telefone16176556580
Sitehttps://www.vorbio.com/
Código da empresaVOR
Data de listagemFeb 05, 2021
Fundado em2015
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Han Choi, M.D.
Dr. Han Choi, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Robert Ang, M.D.
Dr. Robert Ang, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Tirtha Chakraborty, Ph.D.
Dr. Tirtha Chakraborty, Ph.D.
Chief Scientific Officer and Head of Technical Operations
Chief Scientific Officer and Head of Technical Operations
80.28K
-3.40%
Mr. Matthew R. Patterson
Mr. Matthew R. Patterson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
41.20K
+3.36%
Dr. Sven Ante (Bill) Lundberg, M.D.
Dr. Sven Ante (Bill) Lundberg, M.D.
Independent Director
Independent Director
29.43K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sex, 18 de abr
Tempo de atualização: sex, 18 de abr
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
Estatísticas dos acionistas
Acionista
Proporção
RA Capital Management, LP
31.75%
Reprogrammed Interchange LLC
31.22%
5AM Ventures
5.10%
Fidelity Management & Research Company LLC
5.07%
The Vanguard Group, Inc.
1.56%
Other
25.31%
Tipo
Acionista
Proporção
Hedge Fund
33.29%
Corporation
31.22%
Investment Advisor
7.09%
Venture Capital
6.26%
Investment Advisor/Hedge Fund
2.57%
Individual Investor
0.70%
Research Firm
0.21%
Bank and Trust
0.01%
Other
18.65%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
171
101.61M
81.40%
+39.01M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
2022Q4
162
61.21M
94.78%
+26.97M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
39.65M
31.75%
+16.90M
+74.28%
Dec 31, 2024
Reprogrammed Interchange LLC
38.97M
31.22%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.1%
--
--
Dec 31, 2024
Fidelity Management & Research Company LLC
6.33M
5.07%
-649.38K
-9.30%
Dec 31, 2024
The Vanguard Group, Inc.
1.94M
1.56%
-11.46K
-0.59%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Dec 31, 2024
Lynx1 Capital Advisors LLC
637.22K
0.51%
+637.22K
--
Dec 31, 2024
Sarissa Capital Management, L.P.
618.00K
0.49%
--
--
Dec 31, 2024
Ang (Robert M.D.)
646.69K
0.52%
+131.47K
+25.52%
Feb 06, 2025
Renaissance Technologies LLC
529.50K
0.42%
-226.51K
-29.96%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: ter, 6 de mai
Tempo de atualização: ter, 6 de mai
Nome
Proporção
Range Cancer Immunotherapy ETF
1.25%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Ver Mais
Range Cancer Immunotherapy ETF
Proporção1.25%
iShares Micro-Cap ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Global X Russell 2000 Covered Call ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados